Fluorescence in situ hybridization for detecting transitional cell carcinoma: implications for clinical practice
- 15 November 2005
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 96 (9), 1280-1285
- https://doi.org/10.1111/j.1464-410x.2005.05826.x
Abstract
To determine the diagnostic sensitivity of genetic studies using fluorescence in situ hybridization (FISH) for detecting both new and recurrent cases of transitional cell carcinoma (TCC) in a routine clinical practice setting, as bladder cancer has a significant risk of recurrence and progression to invasive disease and thus sensitive surveillance testing is very important. FISH was performed using the UroVysion kit (Vysis Inc., Downers Grove, IL, USA) Consecutive patients were assessed using FISH, both to evaluate those with a history of TCC or with suspicious symptoms, and the FISH results were compared with concurrent biopsy and cytological assessments. In all, 521 consecutive FISH tests from 300 patients were evaluated; 47% had a history of bladder cancer and 53% had suspicious symptoms. Of the 521 FISH tests, 24% were positive; concurrent cytology was available for 84% of the FISH tests, with a concordance rate of 78% (6% were positive for both and 72% were negative by both tests). For the discordant cases, FISH was positive and cytology negative in 21% of cases, and cytology was positive with a negative FISH for 1%. In all, 99 FISH tests had concurrent biopsy data. Of the 44 cases histologically positive for TCC, 32 were FISH-positive, resulting in an overall sensitivity (95% confidence interval) of 73 (60-88)%. FISH detected 95% of cases with high-grade carcinoma, while only seven of these 17 were positive by concurrent cytological assessment. FISH detected 56% and cytology detected 32% of low-grade lesions. FISH detected all nine new cases with positive histology. Overall, the specificity of FISH was 65 (53-78)%. Of 112 patients with previous TCC, 28 had a recurrence; 22 of these had positive FISH results. FISH analysis has a high sensitivity for detecting new cases of TCC, as well as recurrences. From the present data FISH is considerably more sensitive and only slightly less specific than cytology in diagnosing TCC. Therefore, we recommend FISH as a useful initial diagnostic tool in patients suspected of both new and recurrent TCC.Keywords
This publication has 15 references indexed in Scilit:
- Multitarget Fluorescence In Situ Hybridization Assay Detects Transitional Cell Carcinoma in the Majority of Patients with Bladder Cancer and Atypical or Negative Urine CytologyJournal of Urology, 2003
- Evaluation of fluorescence in situ hybridization as an ancillary tool to urine cytology in diagnosing urothelial carcinomaDiagnostic Cytopathology, 2003
- Fluorescence In Situ Hybridization as an Ancillary Tool in Urine Cytology to Diagnose Urothelial CarcinomaPathology Case Reviews, 2002
- A study comparing various noninvasive methods of detecting bladder cancer in urineBJU International, 2002
- Multiprobe FISH for Enhanced Detection of Bladder Cancer in Voided Urine Specimens and Bladder WashingsAmerican Journal of Clinical Pathology, 2001
- Cancer Statistics, 2001CA: A Cancer Journal for Clinicians, 2001
- A COMPARISON OF CYTOLOGY AND FLUORESCENCE IN SITU HYBRIDIZATION FOR THE DETECTION OF UROTHELIAL CARCINOMAJournal of Urology, 2000
- A COMPARISON OF CYTOLOGY AND FLUORESCENCE IN SITU HYBRIDIZATION FOR THE DETECTION OF UROTHELIAL CARCINOMAJournal of Urology, 2000
- The Development of a Multitarget, Multicolor Fluorescence in Situ Hybridization Assay for the Detection of Urothelial Carcinoma in UrineThe Journal of Molecular Diagnostics, 2000
- Does Flexible Cystoscopy miss more Tumours than Rod‐lens Examination?British Journal of Urology, 1993